Dietary Polyphenols Show Promise in Reversing Epigenetic Age Markers in Clinical Trial

Can Dietary Polyphenols Turn Back the Aging Clock?

Higher consumption of specific plant compounds dubbed "methyl adaptogens" significantly reduced epigenetic age in healthy middle-aged men, researchers report in a secondary analysis of the Methylation Diet and Lifestyle clinical trial. The findings, published in Aging journal, reveal that polyphenol-rich foods including turmeric, garlic, berries, green tea, and rosemary were independently associated with biological age reversal, accounting for nearly half the observed variability in epigenetic aging outcomes.

The analysis delved deeper into data from the original eight-week randomized controlled trial that demonstrated a significant 3.14-year difference in epigenetic age between the intervention and control groups. Researchers sought to identify which specific dietary components drove the observed age-reversing effects, analyzing self-reported dietary intake alongside biological markers. The intervention included an omnivorous but plant-centered diet that eliminated added sugar, trans-fats, grains, legumes, dairy, and alcohol while emphasizing foods containing vitamins and polyphenolic compounds shown in preclinical studies to influence DNA methylation pathways. Consumption of colorful vegetables, cruciferous vegetables, and methyl adaptogens showed the strongest associations with reduced epigenetic age. Methyl adaptogens emerged as particularly significant, with their consumption remaining strongly associated with epigenetic age reduction even after adjusting for weight changes and baseline epigenetic age acceleration. The relationship between methyl adaptogen consumption and epigenetic age reduction was dose-dependent, suggesting a potential mechanistic relationship rather than merely an association. Blood levels of methyltetrahydrofolate, a marker of green vegetable intake, were significantly higher in the intervention group, providing biological validation of dietary adherence beyond self-reporting.

How Do Polyphenols Influence Epigenetic Aging?

The researchers propose several mechanisms through which polyphenols may reduce epigenetic aging. "Polyphenols in methyl adaptogens may reduce epigenetic aging through multiple mechanisms," the authors note. "One such pathway involves the modulation of DNA methyltransferases, enzymes responsible for adding methyl groups to DNA." Compounds such as epigallocatechin gallate from green tea, allicin from garlic, anthocyanins from berries, curcumin from turmeric, and rosmarinic acid from rosemary have been shown to inhibit DNA methyltransferases and regulate gene expression associated with accelerated epigenetic aging. These compounds also influence telomerase activity and modulate the PIK3/AKT/mTOR signaling pathways, which govern cellular functions including proliferation, metabolism, and survival. Disruptions in these pathways are implicated in aging-related diseases such as cardiovascular, endocrine, and neurodegenerative conditions, as well as cancer. "Preclinical studies indicate that these compounds selectively induce apoptosis in malignant cells while maintaining telomere integrity in healthy cells, emphasizing their potential to safely mitigate aging processes," the researchers explain.

Are Nutritional Approaches Outpacing Caloric Restriction Trends?

Interestingly, weight loss during the study did not significantly predict reductions in epigenetic age in the regression model, differing from research that links caloric restriction to delayed biological aging. This contrasts with the approach of companies like Calico Life Sciences (Google/Alphabet) and Altos Labs, which have invested heavily in caloric restriction mimetics. The findings align more closely with nutritional approaches to longevity, similar to the "green Mediterranean diet" interventions studied in the DIRECT PLUS trial, which found associations between dietary polyphenols, polyphenol metabolites, and slower biological aging. This places the research in line with companies like Elysium Health, which markets supplements targeting NAD+ metabolism, and ChromaDex, which produces nicotinamide riboside supplements. The study's dietary approach differs from single-compound interventions by leveraging potential synergistic effects of multiple polyphenols consumed as whole foods rather than isolated supplements.

Dr. Kara Fitzgerald, the study's lead author, emphasized the potential significance of the findings despite limitations: "The results of this secondary analysis suggest that consumption of foods categorized as methyl adaptogens due to their potential to be polyphenolic regulators of DNA methylation were associated with epigenetic age reduction in healthy, middle-aged men." The researchers acknowledge several limitations, including the small sample size (n=38), the reliance on self-reported dietary data, and the homogeneity of participants (all male, 81% white). The study also did not track adherence to sleep and stress reduction recommendations, which may have contributed to the variability in epigenetic age changes. Despite these limitations, the regression model developed accounted for 44% of the variability observed in epigenetic age change during the trial, suggesting a robust effect of the dietary intervention. The researchers call for future studies with larger, more diverse populations to enhance generalizability and to utilize extrinsic epigenetic age measures to determine the intervention's relevance in mitigating future morbidity and mortality.

This study comes amid growing industry interest in targeting biological aging processes rather than individual age-related diseases. Major pharmaceutical companies including Pfizer, GSK, and Novartis have invested in aging research, while specialized biotechs like Unity Biotechnology, Juvenescence, and Life Biosciences focus specifically on developing therapeutics targeting aging mechanisms. The approach demonstrated in this study – using dietary interventions to modulate epigenetic markers of aging – represents a complementary strategy to pharmaceutical development, potentially offering a lower-risk intervention that could be implemented alongside conventional medical approaches. As the global population ages and healthcare systems face mounting challenges from age-related diseases, interventions that can delay the onset of multiple chronic conditions simultaneously are gaining attention from healthcare providers, insurers, and investors alike.

Which Biomarkers Signal a Successful Intervention?

The study also provides important insights into baseline epigenetic age acceleration (EAA) as a predictor of intervention response. Participants who were epigenetically older than their chronological age at baseline showed greater reductions in epigenetic age during the intervention. This finding aligns with emerging evidence that individuals with accelerated epigenetic aging may benefit most from targeted interventions, suggesting a potential avenue for personalized approaches to biological age reversal. The hierarchical linear regression analysis revealed that baseline EAA significantly predicted epigenetic age change (p = 0.007), with higher values of baseline EAA associated with greater reductions in epigenetic age.

Another notable aspect of the study was the measurement of methyltetrahydrofolate (MF) blood levels as a biomarker of adherence to the dietary protocol. The intervention group showed a significant increase in MF levels compared to the control group, providing objective evidence that participants were consuming folate-rich foods as recommended. This biomarker validation strengthens the study's findings by confirming adherence beyond self-reported dietary data, which is often subject to recall bias and inaccuracies.

The researchers employed Horvath's 2013 pan-tissue algorithm to measure epigenetic age from saliva samples, noting that this measure is reliably robust when evaluating multiple tissue types. However, they acknowledge that utilizing multiple algorithms could allow for a better understanding and assessment of the clinical relevance of the findings. Recent advances in epigenetic clock development have produced more specialized measures that may offer additional insights into the mechanisms and effects of dietary interventions on biological aging.

Industry Context: This research contributes to the rapidly evolving landscape of "longevity medicine," where interventions targeting fundamental aging processes are increasingly seen as viable approaches to extending healthspan. While pharmaceutical and biotech companies continue pursuing single-molecule solutions for age-related disorders, this study highlights the potential of dietary polyphenols as accessible, food-based interventions that may modify epigenetic markers of aging. The challenge remains translating these findings into practical, scalable recommendations for the general population, particularly given the requirement for significant dietary modifications that may be difficult to sustain long-term. The field continues to await longitudinal studies that can demonstrate whether short-term changes in epigenetic age markers translate to meaningful improvements in healthspan and reductions in age-related disease burden.

Summary

The research examined data from an eight-week randomized controlled trial that demonstrated a 3.14-year reduction in epigenetic age through dietary intervention. The study found that methyl adaptogens from foods like turmeric, garlic, berries, and green tea were strongly associated with biological age reversal, accounting for nearly half of the observed changes. The plant-centered diet eliminated processed foods while emphasizing polyphenol-rich ingredients. The results showed that polyphenols influence aging through multiple mechanisms, including DNA methyltransferase modulation and telomerase activity regulation. Despite limitations such as small sample size and homogeneous participant group, the findings suggest that dietary interventions could offer a promising approach to targeting biological aging processes, complementing pharmaceutical developments in longevity medicine.